Halozyme Therapeutics HALO
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 65th percentile, 5-year average 21.1x
#1903 of 2996 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 1st percentile, 5-year average 38.1x
#5286 of 5338 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 7th percentile, 5-year average 8.2x
#4169 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -188.35 | – | 38.12 | 1% (cheaper than usual) | #5286 of 5338 (1 = cheapest) |
| PE | 22.84 | 9.28 | 21.10 | 65% (pricier than usual) | #1903 of 2996 (1 = cheapest) |
| PS | 5.78 | 4.91 | 8.18 | 7% (cheaper than usual) | #4169 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on HALO.
Sign in to join the discussion.